Why Bipolar Disorder Cannot Simply Be Stopped During Pregnancy

The single most dangerous approach to bipolar disorder in pregnancy is abruptly stopping mood-stabilizing medication without a careful plan. This decision — driven by appropriate concern for fetal medication exposure — dramatically increases the risk of a mood episode during the pregnancy, which carries its own significant risks to both mother and fetus.

The relapse risk following discontinuation of mood stabilizers in bipolar disorder is high in the general population; during pregnancy, it is even higher because pregnancy itself is a period of significant hormonal, physiological, and psychosocial change that destabilizes mood. Studies find that women with bipolar disorder who stop mood stabilizers during pregnancy have significantly higher rates of mood episodes — including severe postpartum mania and depression — than those who continue treatment with appropriate monitoring.

The risks of untreated bipolar episodes during pregnancy include: elevated fetal cortisol exposure from sustained maternal stress-response activation; impaired prenatal care driven by depressive or manic episodes that reduce the mother’s capacity to maintain self-care and engage with obstetric appointments; preterm birth risk associated with severe mental illness during pregnancy; and the elevated postpartum episode risk that follows untreated prenatal illness.

The risk-benefit calculation for bipolar disorder in pregnancy is therefore not “medication risk versus no risk.” It is “medication risk versus untreated bipolar disorder risk.” For most women with bipolar disorder, the risks of untreated illness significantly exceed the risks of carefully selected and monitored medication.

Medication Considerations by Class

The mood stabilizer choices for bipolar disorder in pregnancy involve careful weighing of medication-specific risks against illness severity and individual history.

Lithium has been used in pregnancy for decades and has the most extensive safety data. It carries a small absolute risk of cardiac malformations (Ebstein anomaly) that is smaller than earlier reports suggested — the absolute risk increase is approximately 1–2 per 1,000 exposures above the baseline rate. Lithium requires more frequent monitoring during pregnancy because renal lithium clearance increases, requiring dose adjustments to maintain therapeutic levels. It is generally considered a viable option for women whose bipolar disorder requires lithium specifically for adequate control.

Valproate (valproic acid) is specifically contraindicated in pregnancy due to significant teratogenicity — neural tube defects, cardiac malformations, and cognitive impairment in exposed children. It is the mood stabilizer with the clearest contraindication and should be avoided in women who are or may become pregnant. Women of childbearing age on valproate should have an explicit contraception and pregnancy planning conversation.

Lamotrigine has a more favorable pregnancy safety profile than valproate. The rate of major congenital malformations is comparable to background rates in most studies, though oral cleft risk may be modestly elevated at higher doses. Lamotrigine levels drop significantly during pregnancy due to increased hepatic metabolism, requiring dose increases to maintain therapeutic levels; this requires frequent monitoring throughout pregnancy.

Atypical antipsychotics (quetiapine, olanzapine, aripiprazole) are increasingly used in bipolar disorder during pregnancy when mood stabilizers are insufficient or contraindicated. Safety data for these agents in pregnancy are growing but less extensive than for lithium or lamotrigine. Metabolic monitoring is important as gestational diabetes risk may be elevated.

The Clinical Approach and Why Expertise Matters

Managing bipolar disorder during pregnancy requires expertise that combines understanding of bipolar disorder pharmacology, reproductive psychiatry, and the specific physiological changes of pregnancy that affect drug metabolism and illness course. This is not a clinical situation that is well-managed by either an obstetric provider alone or a general psychiatrist without reproductive psychiatry training.

The ideal management approach involves: preconception counseling for women with bipolar disorder who are planning pregnancy, allowing medication optimization before conception; close collaboration between the psychiatric and obstetric providers throughout the pregnancy; individualized risk-benefit analysis for the specific medications that have controlled the patient’s bipolar disorder; frequent mood monitoring with validated bipolar-specific instruments; and a specific postpartum mood monitoring and treatment plan given the elevated postpartum episode risk in women with bipolar disorder.

Women with bipolar disorder who become pregnant unexpectedly on a teratogenic medication (particularly valproate) require urgent consultation to develop a management plan. Abrupt discontinuation of valproate without a plan is not the right response; a rapid transition under psychiatric guidance to a safer alternative is.

ETX Psychiatry provides bipolar disorder medication management with awareness of reproductive safety data. For pregnant patients or those planning pregnancy, we coordinate closely with obstetric providers. Call (430) 288-5800 or schedule online. We accept Medicare, Aetna, BCBS, Cigna, Optum, UHC, UMR, and Ambetter. 100 Independence Pl, Suite 405, Tyler, TX 75703. Telehealth available.

Postpartum: The Highest-Risk Period

The postpartum period is the highest-risk time for bipolar disorder episodes — higher than pregnancy itself. Women with bipolar disorder have significantly elevated rates of postpartum mania, postpartum psychosis, and severe postpartum depression compared to the general population. For women with a prior history of postpartum episodes, the recurrence risk is particularly high.

Postpartum mood monitoring should begin before discharge from the hospital and continue with frequent check-ins through the first three months postpartum. Sleep disruption from infant care is a major bipolar trigger, and the extreme sleep deprivation of the newborn period is a direct mood destabilizer. Planning for sleep support in the postpartum period is a clinical priority for women with bipolar disorder, not just a logistical convenience.

Women with bipolar disorder who breastfeed need explicit guidance on medication compatibility with breastfeeding. Most mood stabilizers pass into breast milk to varying degrees, and breastfeeding decisions should be made with psychiatric and obstetric guidance rather than general internet advice. ETX Psychiatry provides this guidance in the context of comprehensive ongoing care. Call (430) 288-5800.